Abstract Search

ey0020.2-9 | Long-Acting Growth Hormone (LAGH) | ESPEYB20

2.9. Safety and efficacy of lonapegsomatropin in children with growth hormone deficiency: enliGHten trial 2-year results

AK Maniatis , SJ Casella , UM Nadgir , PL Hofman , P Saenger , ED Chertock , EM Aghajanova , M Korpal-Szczyrska , E Vlachopapadopoulou , O Malievskiy , T Chaychenko , M Cappa , W Song , M Mao , PH Mygind , AR Smith , SD Chessler , AS Komirenko , M Beckert , AD Shu , PS Thornton

Brief summary: This open-label extension trial enrolled all subjects completing the two previous phase 3 Lonapegsomatropin trials, heiGHt and fliGHt. The results confirm the efficacy of this LAGH formulation in improving height SDS, without major adverse events.Lonapegsomatropin is a long-acting GH consisting of 3 components: unmodified human GH (hGH), an inert glycol carrier, and a TransCon linker that transiently binds the other 2 components. The glyco...

3 shares

ESPE Yearbook of Paediatric Endocrinology

2.9. Safety and efficacy of lonapegsomatropin in children with growth hormone deficiency: enliGHten trial 2-year results

BiosciAbstracts